RCAR (RenovaCare) YoY EBITDA Growth: 73.68% (As of Sep. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is RenovaCare YoY EBITDA Growth?

RenovaCare RCAR -99.00% YoY EBITDA Growth is 73.68% as of Sep. 2022.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. RenovaCare's YoY EBITDA Growth for the quarter that ended in Sep. 2022 was 73.68%.

RenovaCare's EBITDA per Share for the three months ended in Sep. 2022 was $-0.01.

RenovaCare YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for RenovaCare's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RenovaCare YoY EBITDA Growth Chart

RenovaCare Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -33.33 27.78 -61.54 -164.29 44.14

RenovaCare Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.42 10.34 -233.33 -160.00 73.68

RenovaCare YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

RenovaCare's YoY EBITDA Growth for the fiscal year that ended in Dec. 2021 is calculated as:

YoY EBITDA Growth (A: Dec. 2021 )
=(EBITDA per Share (A: Dec. 2021 )-EBITDA per Share (A: Dec. 2020 ))/ | EBITDA per Share (A: Dec. 2020 ) |
=(-0.062--0.111)/ | -0.111 |
=44.14 %

RenovaCare's YoY EBITDA Growth for the quarter that ended in Sep. 2022 is calculated as:

YoY EBITDA Growth (Q: Sep. 2022 )
=(EBITDA per Share (Q: Sep. 2022 )-EBITDA per Share (Q: Sep. 2021 )) / | EBITDA per Share (Q: Sep. 2021 )) |
=(-0.005--0.019)/ | -0.019 |
=73.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 73.68% mean?
RenovaCare (RCAR) has a YoY EBITDA Growth of 73.68% as of Sep. 2022. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for RenovaCare and its competitors.
Is RenovaCare's YoY EBITDA Growth too high?
RenovaCare's current YoY EBITDA Growth is 73.68%.
How does RenovaCare's YoY EBITDA Growth compare to ONCSQ and STAB?
RenovaCare's YoY EBITDA Growth of 73.68% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for RenovaCare and its competitors. RenovaCare's current YoY EBITDA Growth is 73.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RenovaCare stock overvalued right now?
RenovaCare (RCAR) has a current YoY EBITDA Growth of 73.68%. The current YoY EBITDA Growth is 73.68%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For RenovaCare (RCAR), the current YoY EBITDA Growth is 73.68% as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RenovaCare Business Description

Address 9375 East Shea Boulvard, Suite 107-A, Scottsdale, AZ, USA, 85260
RenovaCare Inc is a biotechnology company focusing on the acquisition, research, development and commercialization of autologous cellular therapies that can be used for medical and aesthetic applications. The company's initial products under development target skin. It offers treatment methodology for cell isolation for the regeneration of human skin cells, along with a medical-grade liquid spraying device and associated equipment (the SkinGun). RenovaCare is evaluating the efficacy and potential of SkinGun, in combination with a cell isolation method, in the treatment of tissue that has been subject to severe trauma. Geographically all the activities are functioned through the region of United States.